Routine clinical use of nab-paclitaxel for advanced / metastatic breast cancer in Germany: Final results of the prospective observational study NABUCCO. 7. Juli 2017 Schroeder, J., Potthoff, K., Salat, C., Soeling, U., Hansen, R., Grebhardt, S., Harde, J., Nusch, A., Marschner, N., 2017. J Clin Oncol 35(suppl; abstr e12555). doi:10.1200/JCO.2017.35.15_suppl.e12555 Abstract Persistent impairments 3 years after (neo)adjuvant chemotherapy for breast cancer – results from the MaTox project. Hurtz, H.-J., Tesch, H., Göhler, T., Hutzschenreuter, U., Harde, J., Kruggel, L., Jänicke, M., Marschner, N., TMK-Group (Tumour Registry Breast Cancer), 2017. Breast Cancer Res… Weiterlesen Predicting early treatment discontinuation and effectiveness in bevacizumab-treated patients with advanced ovarian cancer: Exploratory analyses of the OTILIA study (on behalf of NOGGO) Wimberger, P., Woopen, H., Mustea, A., Oskay-Oezcelik, G., Keller, M., Harde, J., Richter, R., Wegenaer, A., Klawitter, S., Tomé, O., Sehouli, J., 2017. ESGO7–0321 (PS19)… Weiterlesen